Viking Therapeutics, Inc.
NASDAQ:VKTX
Overview | Financials
Company Name | Viking Therapeutics, Inc. |
Symbol | VKTX |
Currency | USD |
Price | 34.86 |
Market Cap | 3,884,658,960 |
Dividend Yield | 0% |
52-week-range | 20.28 - 99.41 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Brian Lian Ph.D. |
Website | https://www.vikingtherapeutics.com |
An error occurred while fetching data.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD